PPP2CA Rekombinanter Antikörper

PPP2CA Rekombinant Antikörper für WB, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, ELISA

Konjugation

Unkonjugiert

CloneNo.

241112B8

Kat-Nr. : 84155-5-RR

Synonyme

PP2CA, PP2Ac, PP2A-alpha, PP2A alpha, EC:3.1.3.16

---

• 

  WB analysis using 84155-5-RR

  Various lysates were subjected to SDS PAGE followed by western blot with 84155-5-RR (PPP2CA antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours.

• 

  Affinity and Kinetic Characterization of 84155-5-RR

  Biolayer interferometry (BLl) kinetic assays of 84155-5-RR against Human PPP2CA were performed. The affinity constant is 13.6 nM.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: MCF-7-Zellen, Jurkat-Zellen

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:2000-1:10000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

84155-5-RR bindet in WB, ELISA PPP2CA und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Rekombinant
• Typ: Antikörper
• Immunogen: PPP2CA fusion protein Ag4294
• Vollständiger Name: protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform
• Berechnetes Molekulargewicht: 309 aa, 36 kDa
• Beobachtetes Molekulargewicht: 36 kDa
• GenBank-Zugangsnummer: BC031696
• Gene symbol: PPP2CA
• Gene ID (NCBI): 5515
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Protein A purfication
• Lagerungspuffer: PBS with 0.02% sodium azide and 50% glycerol
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

PPP2CA, also named as RP-C and PP2A-alpha, belongs to the PPP phosphatase family and PP-1 subfamily. PP2A can modulate the activity of phosphorylase B kinase casein kinase 2, mitogen-stimulated S6 kinase, and MAP-2 kinase. PP2A activity was modestly decreased in AML patients harboring C-KIT/WT.PP2A is a target for C-KIT/TKD and implicated the potential efficacy of therapies targeting PP2A in such AML in future.